CINECA IRIS Institutional Research Information System

GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.521
NA - Nord America 1.054
AS - Asia 399
AF - Africa 29
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.010
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 1.213
US - Stati Uniti d'America 1.046
SG - Singapore 179
CN - Cina 112
SE - Svezia 98
CH - Svizzera 72
IN - India 67
DE - Germania 39
CI - Costa d'Avorio 24
GB - Regno Unito 23
PL - Polonia 22
HK - Hong Kong 20
BG - Bulgaria 13
RU - Federazione Russa 13
CZ - Repubblica Ceca 10
CA - Canada 8
FI - Finlandia 8
TR - Turchia 6
BR - Brasile 5
JP - Giappone 5
VN - Vietnam 5
SN - Senegal 3
TW - Taiwan 3
AT - Austria 2
FR - Francia 2
IE - Irlanda 2
NG - Nigeria 2
TH - Thailandia 2
CL - Cile 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
NL - Olanda 1
UA - Ucraina 1
Totale 3.010
Salva come PNG Salva come JPEG
Città #
Milan 778
Santa Clara 418
Boardman 137
Pisa 111
New York 105
Singapore 103
Rome 82
Bern 72
Hyderabad 59
Fairfield 57
Seattle 42
Ashburn 36
Frankfurt am Main 33
Woodbridge 31
Florence 26
Abidjan 24
Warsaw 22
Chicago 21
Hong Kong 18
Houston 18
Shanghai 18
Wilmington 17
Cambridge 15
Chandler 15
Ann Arbor 14
London 14
Serra 14
Sofia 13
Fuzhou 10
Brno 8
Ottawa 7
Pune 7
Beijing 5
Lawrence 5
Medford 5
Princeton 5
Tokyo 5
Chiswick 4
Des Moines 4
Istanbul 4
Nocera Superiore 4
Zhengzhou 4
Dakar 3
Gainesville 3
Guangzhou 3
Lappeenranta 3
Ogden 3
Quanzhou 3
San Diego 3
Shenzhen 3
São Paulo 3
Tübingen 3
Bremen 2
Capaccio 2
Carrara 2
Castano Primo 2
Clemson 2
Dearborn 2
Dublin 2
Fort Worth 2
Fossombrone 2
Izmir 2
Lagos 2
Messina 2
Nanjing 2
Padova 2
Paris 2
Pontedera 2
Seravezza 2
Shijiazhuang 2
Springfield 2
Taichung 2
Taubaté 2
Udon Thani 2
Vienna 2
Viterbo 2
Wenzhou 2
Wuhan 2
Čelákovice 2
Altopascio 1
Bhubaneswar 1
Changsha 1
Chengdu 1
Clifton 1
Dallas 1
Dongguan 1
Genoa 1
Hackney 1
Harbin 1
Helsinki 1
Heze 1
Jiaxing 1
Kent 1
Kilburn 1
Laojunmiao 1
Livorno 1
Longshan 1
Los Angeles 1
Modena 1
Nanchang 1
Totale 2.495
Salva come PNG Salva come JPEG
Nome #
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 99
B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma 92
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection 82
HCV-related rheumatic manifestations and therapeutic strategies 81
Treatment of HCV-related mixed cryoglobulinemia 79
IgG cryoglobulinemia 74
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 60
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 53
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 53
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study 52
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 52
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 51
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 50
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 50
HCV infection, malignancy and liver transplantation 50
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 49
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 49
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 48
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 48
Non-Invasive B-Cell Clonality Markers May Help in the Rational Approach to HCV Svr Cryoglobulinemic Patients with Persisting Manifestations 48
Detection of WA B Cells in HCV Infection by Molecular Analysis: A Prognostic Marker for Cryoglobulinemic Vasculits and B Cell Lymphomas 47
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 47
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 47
P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases 47
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 46
The Hepatitis C Virus Infection as a Systemic Disease 46
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 46
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 46
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 45
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 45
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1 45
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 45
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 45
Host genetic determinants in HCV-related mixed cryoglobulinemia 44
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 44
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 44
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 44
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 44
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 43
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection 43
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 43
HCV and lymphoproliferation 43
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection 42
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 42
Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study 41
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment 41
NOTCH4 AND MHC CLASS II POLYMORPHISMS CONTRIBUTE TO HCV-RELATED BENIGN AND MALIGNANT LYMPHOPROLIFERATIVE DISEASES 40
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 35
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 34
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 30
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 29
Thyroid Autoimmunity and SARS-CoV-2 Infection 28
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 27
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 24
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 21
HCV AND lymphoma: Genetic and epigenetic factors 21
Assessment of Free Light Chains in HCV positive patients undergoing Rituximab treatment 21
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies 20
Host genetic determinants in HCV-related mixed cryoglobulinemia 19
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 19
Serological and Molecular Characterization of Hepatitis C Virus-Related Cryoglobulinemic Vasculitis in Patients without Cryoprecipitate 18
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 17
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 17
Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature 16
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy 16
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 16
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study 16
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 15
Hepatitis C virus lymphotrophism: lessons from a decade of studies 15
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 14
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 14
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 14
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 14
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 13
Free light chains: Eclectic multipurpose biomarker 13
Role of notch receptors in hematologic malignancies 12
Hepatitis b virus-related cryoglobulinemic vasculitis: Review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the italian study group of cryoglobulinemia (gisc) 12
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 11
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 11
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 10
Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study 10
HCV infection and carotid atherosclerosis: evidence in favour of a local viral action inside the plaque 10
HIGH SVR RATES WITH SMV plus SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRRHOSIS OR ADVANCED FIBROSIS: A REAL PRACTICE ANALYSIS FROM A LARGE REGIONAL DATABASE IN TUSCANY, ITALY 9
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 9
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 9
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 9
Fibrosis assessment in patients with HCV or HBV chronic infection 8
PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases 8
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 8
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 8
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 8
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 8
HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY 8
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 8
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 7
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 7
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 7
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 7
Prevalence of bcl-2 recombination in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma 7
Presence of BCL-2 rearranged B-cell clones in chronic HCV infection may negatively influence virological response to treatment 7
Totale 3.189
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.890
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.890
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202068 0 0 0 0 0 10 9 9 24 7 5 4
2020/202136 5 3 4 2 0 0 0 5 1 6 5 5
2021/202275 0 1 5 4 8 15 1 6 2 12 5 16
2022/2023449 8 6 10 4 4 11 257 19 87 11 23 9
2023/20241.613 277 230 325 178 248 134 20 26 5 22 12 136
2024/2025916 126 134 40 122 323 171 0 0 0 0 0 0
Totale 3.290